Skip to main content
S&P 5007,541.40-0.51%DOW51,983.98+0.41%NASDAQ25,164.36-1.07%BTC$77,142.00-1.60%ETH$2,258.53-1.35%GOLD$3,958.40-0.28%OIL$96.61+0.16%
Smart Investors Daily
SID Premium
Biomerica, Inc. logo

NASDAQ · BMRA

Biomerica, Inc.

Healthcare · Medical - Devices

$1.73

Up+$0.01 (+0.58%)

Updated Nov 3, 2026, 4:43 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
7.37M
P/E ratio
-1.86
Dividend yield
0.00%
52-week range
$1.45 – $2.94
Volume
2.92K
Avg. volume
95.23K

Price performance · BMRA

BMRA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

BMRA closed at $1.73 after 21 trading sessions, down 15.61% for the selected period.

Last close
$1.73
Period change
-15.61%
Period low
$1.68
Period high
$2.14
Daily close
View OHLC price history
BMRA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$1.69$1.7724$1.69$1.732.92K
Oct 30, 2026$1.71$1.735$1.68$1.7210.22K
Oct 29, 2026$1.73$1.7494$1.70$1.744.23K
Oct 28, 2026$1.72$1.7707$1.70$1.754.08K
Oct 27, 2026$1.7737$1.79$1.66$1.717.22K
Oct 26, 2026$1.67$1.7899$1.67$1.7210.41K
Oct 23, 2026$1.68$1.72$1.6573$1.6812.49K
Oct 22, 2026$1.66$1.71$1.66$1.682K
Oct 21, 2026$1.69$1.72$1.60$1.717.54K
Oct 20, 2026$1.7675$1.788$1.60$1.71875.97K
Oct 19, 2026$1.85$1.85$1.75$1.7613.29K
Oct 16, 2026$1.83$1.9529$1.81$1.8513.22K
Oct 15, 2026$1.87$1.915$1.81$1.87513.85K
Oct 14, 2026$1.83$1.8599$1.76$1.8018.63K
Oct 13, 2026$1.85$1.89$1.81$1.8513.3K
Oct 12, 2026$1.90$1.90$1.835$1.8355.25K
Oct 9, 2026$1.86$1.87$1.8352$1.835210.3K
Oct 8, 2026$1.91$1.91$1.86$1.896.62K
Oct 7, 2026$2.10$2.10$1.90$1.9134.65K
Oct 6, 2026$2.09$2.14$2.01$2.1411.05K
Oct 5, 2026$2.06$2.19$2.02$2.0533.89K

Latest BMRA news

The latest Smart Investors Daily articles mentioning BMRA.

Stock researchCompany · Overview

BMRA research

Overview

Company profile and research snapshot.

Company profile

Biomerica Inc is engaged in the development, manufacturing, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The company focuses on products for gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. The Company manages its operations as a single operating and reportable segment, which focus on the development, manufacture, marketing, and sale of diagnostic products. The majority of the company's revenue is earned from the Asia, and also has its presence in Europe, North America, Middle East and South America.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
BMRA recent ratings
DateFirmRatingTarget
Oct 19, 2020Aegis CapitalBuy—
Sep 4, 2020Aegis CapitalBuy—
Aug 21, 2020Aegis CapitalBuy—
Dec 17, 2018B. Riley FBRBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 16, 2026

Biomerica Reports First Quarter Fiscal 2027 Financial Results

InFoods® IBS Commercial Progress: Medicare-related test orders increased 120% in September 2026 compared to August, with growing physician participation and repeat ordering activityInFoods® IBS update: 100% of all initial valid Medicare claims processed as of October 15, 2026 have been paid at the full CMS payment rate of $300Engaged B. Riley Securities, Inc. to support the Board's ongoing evaluation of potential strategic opportunities, including partnerships and business combinationsTotal oper

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By